Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2CNS 1

Conditions

Colorectal Neoplasms 315Pancreatic Neoplasms 186Carcinoma, Hepatocellular 116Stomach Neoplasms 110Colonic Neoplasms 84Esophageal Neoplasms 80Carcinoma, Non-Small-Cell Lung 80Breast Neoplasms 78Rectal Neoplasms 75Ovarian Neoplasms 62Neoplasm Metastasis 59Lung Neoplasms 58Neoplasms 54Cholangiocarcinoma 53Melanoma 45Liver Neoplasms 45Gastrointestinal Neoplasms 43Prostatic Neoplasms 42Biliary Tract Neoplasms 37Endometrial Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Sarcoma 29Carcinoma, Renal Cell 29Esophageal Squamous Cell Carcinoma 27Uterine Cervical Neoplasms 26Adenocarcinoma Of Esophagus 24Head and Neck Neoplasms 23Urinary Bladder Neoplasms 22Small Cell Lung Carcinoma 20Gastrointestinal Stromal Tumors 17

Interventions

11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Gastrointestinal × 30 days × Clear all
NCT05636618 2026-05-14

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Perspective Therapeutics

Phase 1/2 Recruiting
300 enrolled
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT05988918 2026-05-14

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
17 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡